Alexander Gorshtein1,2, Ilana Slutzky-Shraga1,2, Eyal Robenshtok1,2, Carlos Benbassat3,2, Dania Hirsch1,2. 1. Endocrine Institute, Rabin Medical Center, Beilinson Hospital, Petach Tikva, Israel. 2. Sackler Faculty of Medicine, Tel Aviv University, Tel Aviv, Israel. 3. Endocrine Institute, Shamir Medical Center (Formerly Assaf Harofeh Medical Center), Beer Yaakov, Israel.
Abstract
OBJECTIVE: Outcomes of patients with cytologically indeterminate thyroid nodules not referred for thyroidectomy have hardly been investigated. We previously reported outcomes of 322 patients with thyroid nodules classified according to the Bethesda System of Reporting Thyroid Cytology (BSRTC) as indeterminate (B3/B4), of whom 123 (38.2%) underwent thyroidectomy. In the present extension study, we investigated adherence and outcomes in the remaining unoperated 199 patients. METHODS: We conducted a file review of 189/199 patients with thyroid nodules cytologically diagnosed as B3 (n = 174) or B4 (n = 15) in 2011-2012 who were conservatively followed at our institution until 2019. RESULTS: Among 174 patients with B3 nodules, 140 (80.4%) underwent repeated ultrasound. Nodular growth was detected in 23 (16.4%), and findings remained stable in 105 (75%). Fine-needle aspiration was repeated in 88/174 patients (50.6%), with B2 results in 62 (70.4%) and B3/B4/B5 in 20 (22.7%). Thyroidectomy was performed in 14/174 patients (8%) in the B3 and 5/15 patients (33%) in the B4 group at a median of 5 years' follow-up; thyroid cancer was diagnosed in 4/14 patients (28.5%) and 3/5 patients (60%), respectively. For B3 patients who remained unoperated, none had evidence of thyroid cancer at last follow-up. A reason for avoiding surgery was documented in 6/10 unoperated B4 patients (1 thyroid lymphoma, 3 died of unrelated causes, 2 were considered inoperable due to advanced age). CONCLUSIONS: Most patients with initially unoperated B3/B4 nodules adhere, at least partially, to active surveillance. For B3 nodules, subsequent thyroidectomy and thyroid cancer detection are rare events, and patients may be safely managed without using molecular markers. Thyroid cancer is diagnosed in most B4 patients who undergo thyroidectomy in our institution.
OBJECTIVE: Outcomes of patients with cytologically indeterminate thyroid nodules not referred for thyroidectomy have hardly been investigated. We previously reported outcomes of 322 patients with thyroid nodules classified according to the Bethesda System of Reporting Thyroid Cytology (BSRTC) as indeterminate (B3/B4), of whom 123 (38.2%) underwent thyroidectomy. In the present extension study, we investigated adherence and outcomes in the remaining unoperated 199 patients. METHODS: We conducted a file review of 189/199 patients with thyroid nodules cytologically diagnosed as B3 (n = 174) or B4 (n = 15) in 2011-2012 who were conservatively followed at our institution until 2019. RESULTS: Among 174 patients with B3 nodules, 140 (80.4%) underwent repeated ultrasound. Nodular growth was detected in 23 (16.4%), and findings remained stable in 105 (75%). Fine-needle aspiration was repeated in 88/174 patients (50.6%), with B2 results in 62 (70.4%) and B3/B4/B5 in 20 (22.7%). Thyroidectomy was performed in 14/174 patients (8%) in the B3 and 5/15 patients (33%) in the B4 group at a median of 5 years' follow-up; thyroid cancer was diagnosed in 4/14 patients (28.5%) and 3/5 patients (60%), respectively. For B3 patients who remained unoperated, none had evidence of thyroid cancer at last follow-up. A reason for avoiding surgery was documented in 6/10 unoperated B4 patients (1 thyroid lymphoma, 3 died of unrelated causes, 2 were considered inoperable due to advanced age). CONCLUSIONS: Most patients with initially unoperated B3/B4 nodules adhere, at least partially, to active surveillance. For B3 nodules, subsequent thyroidectomy and thyroid cancer detection are rare events, and patients may be safely managed without using molecular markers. Thyroid cancer is diagnosed in most B4 patients who undergo thyroidectomy in our institution.
Authors: Kepal N Patel; Trevor E Angell; Joshua Babiarz; Neil M Barth; Thomas Blevins; Quan-Yang Duh; Ronald A Ghossein; R Mack Harrell; Jing Huang; Giulia C Kennedy; Su Yeon Kim; Richard T Kloos; Virginia A LiVolsi; Gregory W Randolph; Peter M Sadow; Michael H Shanik; Julie A Sosa; S Thomas Traweek; P Sean Walsh; Duncan Whitney; Michael W Yeh; Paul W Ladenson Journal: JAMA Surg Date: 2018-09-01 Impact factor: 14.766
Authors: Mayumi Endo; Fadi Nabhan; Kyle Porter; Katie Roll; Lawrence A Shirley; Irina Azaryan; Dena Tonkovich; Jeanette Perlick; Laura E Ryan; Raheela Khawaja; Shumei Meng; John E Phay; Matthew D Ringel; Jennifer A Sipos Journal: Thyroid Date: 2019-07-17 Impact factor: 6.568
Authors: Daniel S Duick; Joshua P Klopper; James C Diggans; Lyssa Friedman; Giulia C Kennedy; Richard B Lanman; Bryan McIver Journal: Thyroid Date: 2012-08-08 Impact factor: 6.568
Authors: Erik K Alexander; Melanie Schorr; Joshua Klopper; Caroline Kim; Jennifer Sipos; Fadi Nabhan; Charles Parker; David L Steward; Susan J Mandel; Bryan R Haugen Journal: J Clin Endocrinol Metab Date: 2013-12-20 Impact factor: 5.958
Authors: Salem I Noureldine; Alireza Najafian; Patricia Aragon Han; Matthew T Olson; Dane J Genther; Eric B Schneider; Jason D Prescott; Nishant Agrawal; Aarti Mathur; Martha A Zeiger; Ralph P Tufano Journal: JAMA Otolaryngol Head Neck Surg Date: 2016-07-01 Impact factor: 6.223
Authors: Salem I Noureldine; Matthew T Olson; Nishant Agrawal; Jason D Prescott; Martha A Zeiger; Ralph P Tufano Journal: JAMA Otolaryngol Head Neck Surg Date: 2015-12 Impact factor: 6.223